Orr Inbar is an entrepreneur and software and A.I. professional with more than 10 years of leadership experience helping small to mid-sized startups in Israel and the U.S. to grow, innovate, scale, ...

Today, over 90% of experimental therapies that reach human trials fail to make it to market, costing the industry $45 billion annually. These failures are primarily due to lack of efficacy and safety ...

Biotech, pharmaceutical and life sciences companies all hope AI will streamline drug development and make it more efficient, and 38% have already adopted the technology, according to Deloitte.

QuantHealth helps pharma implement artificial intelligence for drug development using clinical trial simulation. Orr Inbar, its cofounder and CEO, discusses that — and the long-term effects of AI on ...

Orr Inbar, cofounder and CEO of QuantHealth, discusses how artificial intelligence can predict how patients will respond to therapies still in development, and the role tech has to play in drug ...